Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Med Sci 2013; 10(3):320-330. doi:10.7150/ijms.4609 This issue Cite

Review

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation

Alberto Antonicelli1,5, Stefano Cafarotti2✉, Alice Indini3, Alessio Galli4, Andrea Russo6, Alfredo Cesario7, Filippo Maria Lococo8, Patrizia Russo9, Alberto Franco Mainini5, Luca Giuseppe Bonifati5, Mario Nosotti1, Luigi Santambrogio1, Stefano Margaritora8,10, Pierluigi Maria Granone8, André Emanuel Dutly2

1. Thoracic Surgery and Lung Transplantation Unit, Foundation IRCCS (Scientific Institute for Research Hospitalization and Health Care) “Ca' Granda” General Hospital, University of Milan, Milan, Italy.
2. Thoracic Surgery EOC Unit - San Giovanni Hospital, Bellinzona, Switzerland.
3. Pediatric Oncology Unit, Foundation IRCCS National Cancer Institute (NCI), Milan, Italy.
4. Department of Preclinical Science LITA Vialba, Luigi Sacco Hospital, University of Milan, Milan, Italy.
5. General Thoracic Surgery Unit, Saronno Regional Hospital, Saronno, Italy.
6. Institute of Anestesiology and Intensive Care Medicine, Catholic University of Sacred Heart, Rome, Italy.
7. Deputy Scientific Director, IRCCS San Raffaele Group, Rome, Italy.
8. Division of Thoracic Surgery, Catholic University of Sacred Heart, Rome, Italy.
9. Laboratory of Systems Approaches and Non Communicable Diseases, IRCCS “San Raffaele Pisana”, Rome, Italy.
10. CFO - Florence Cancer Center, Sesto Fiorentino, Italy.

✉ Corresponding author: Cafarotti Stefano, MD. Thoracic Surgery EOC Unit - San Giovanni Hospital, Bellinzona, Switzerland. cafarottistefanocom. Tel 0039 3207660702 / 0041 (0) 787949238 Fax 0039 0630156329.

Citation:
Antonicelli A, Cafarotti S, Indini A, Galli A, Russo A, Cesario A, Lococo FM, Russo P, Mainini AF, Bonifati LG, Nosotti M, Santambrogio L, Margaritora S, Granone PM, Dutly AE. EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. Int J Med Sci 2013; 10(3):320-330. doi:10.7150/ijms.4609. https://www.medsci.org/v10p0320.htm
Other styles

File import instruction

Abstract

The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs).

This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient-tailored therapy could be closer than commonly expected.

Keywords: EGFR targeted therapy, NSCLC, advanced, mutation, TKIs, resistance.

Citation styles

APA
Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., Lococo, F.M., Russo, P., Mainini, A.F., Bonifati, L.G., Nosotti, M., Santambrogio, L., Margaritora, S., Granone, P.M., Dutly, A.E. (2013). EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. International Journal of Medical Sciences, 10(3), 320-330. https://doi.org/10.7150/ijms.4609.

ACS
Antonicelli, A.; Cafarotti, S.; Indini, A.; Galli, A.; Russo, A.; Cesario, A.; Lococo, F.M.; Russo, P.; Mainini, A.F.; Bonifati, L.G.; Nosotti, M.; Santambrogio, L.; Margaritora, S.; Granone, P.M.; Dutly, A.E. EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. Int. J. Med. Sci. 2013, 10 (3), 320-330. DOI: 10.7150/ijms.4609.

NLM
Antonicelli A, Cafarotti S, Indini A, Galli A, Russo A, Cesario A, Lococo FM, Russo P, Mainini AF, Bonifati LG, Nosotti M, Santambrogio L, Margaritora S, Granone PM, Dutly AE. EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. Int J Med Sci 2013; 10(3):320-330. doi:10.7150/ijms.4609. https://www.medsci.org/v10p0320.htm

CSE
Antonicelli A, Cafarotti S, Indini A, Galli A, Russo A, Cesario A, Lococo FM, Russo P, Mainini AF, Bonifati LG, Nosotti M, Santambrogio L, Margaritora S, Granone PM, Dutly AE. 2013. EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. Int J Med Sci. 10(3):320-330.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use